A Safety and Tolerability Study of NC762 in Subjects With Advanced or Metastatic Solid Tumors
Summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
- Han Myint, MD
NextCure, Inc.
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
8 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Yale Cancer Center
New Haven, Connecticut, United States
- the University of Chicago Medicine and Biological Sciences
Chicago, Illinois, United States
- John Theurer Cancer Center at Hackensack University Medical Center
Hackensack, New Jersey, United States
- Roswell Park Cancer Institute
Buffalo, New York, United States
- Carolina Biooncology Institute
Huntersville, North Carolina, United States
- Gettysburg Cancer Center
Gettysburg, Pennsylvania, United States
- Upmc Hillman Cancer Center
Pittsburgh, Pennsylvania, United States
- Inova Schar Cancer Institute
Fairfax, Virginia, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 30 Jun 2021
- Primary completion
- 30 Jan 2024
- Completion
- 30 Jan 2024
- Last update posted
- 22 Apr 2025
- Registered enrollment
- 40
- Registry id
- NCT04875806
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.